Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Treasury Shares (2016 - 2025)

Rocket Pharmaceuticals' Treasury Shares history spans 5 years, with the latest figure at $47000.0 for Q2 2023.

  • For Q2 2023, Treasury Shares changed N/A year-over-year to $47000.0; the TTM value through Jun 2023 reached $47000.0, changed N/A, while the annual FY2022 figure was $47000.0, N/A changed from the prior year.
  • Treasury Shares for Q4 2025 was $5.0 million at Rocket Pharmaceuticals, up from $17415.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $6.1 million in Q4 2024 and bottomed at $2571.0 in Q4 2022.
  • The 5-year median for Treasury Shares is $69661.0 (2025), against an average of $1.2 million.
  • The largest annual shift saw Treasury Shares plummeted 92.07% in 2019 before it tumbled 77.91% in 2020.
  • A 4-year view of Treasury Shares shows it stood at $53000.0 in 2019, then surged by 43.4% to $76000.0 in 2020, then tumbled by 38.16% to $47000.0 in 2022, then changed by 0.0% to $47000.0 in 2023.
  • Per Business Quant, the three most recent readings for RCKT's Treasury Shares are $47000.0 (Q2 2023), $47000.0 (Q1 2023), and $47000.0 (Q4 2022).